Bharat Biotech Company Prasxfd

www.bharatbiotech.com

Corporate Profile 2012

http://www.bharatbiotech.com/


Fast Facts

Issues

Products

R&D Pipeline

Projects

Recognition

Executive Summary



Fast Facts



Fast Facts Issues Products R&D Pipeline Projects Recognition

Established : 1996

Promoters : Dr. Krishna & Ms. Suchitra Ella

Business Line : Vaccines and Bio-therapeutics

First Project : Hepatitis B Vaccine - US $ 3.5 Mn

Investment : Over US $ 150 Mn till date

Facility : One of the largest facilities in Asia

Personnel : 700 resources including scientists

Accreditations : Korean FDA, ANVISA, other Countries

Innovation : 50 Global patents

Vision

Mission

To offer affordable, safe and effective healthcare

solutions to combat mankind's most dreaded illnesses, and to

thus eradicate or at least control their occurrence in the years to

come.

Developing next-generation remedies through Genetic

Engineering Technologies so as to create a healthier world.

Mission 7 Billion



Issues



Products R&D Pipeline Projects Recognition

Emerging Country Challenges

Lack of clarity on disease burden, public health focus & policies

NEG

LEC

TED

AP

PR

OA

CH

NEG

LEC

TED

DIS

EASE

S

1 TYPHOID

2 HEPATITIS

3 ROTA

4 SCHISTOSOMIASIS

5 E. COLI

6 CHOLERA

7 OTHER DIARRHEA

1 JE

2 DENGUE

3 CHIKUNGUNYA

4 MALARIA

5 TRYPANOSOMA

6 LEISHMANIA

7 FILARIA

POLITICAL COMMITTMENT

SCIENTIFIC COMMITTMENT

Fast Facts Issues




Thinking Future

Today’s neglected diseases - Tomorrow’s global diseases

1 PLAGUE

2 HIV

3 INFLUENZA

4 MALARIA

1 DENGUE

2 CHIKUNGUNYA

3 TRYPANOSOMA

4 LEISHMANIA

5 FILARIA

6 JAPANESE ENCEPHALITIS

Fast Facts Issues

• No DW manufactures develop new vaccines. • Most DW manufactures are biogeneric players. • DC manufactures follow MNCs. • Our Mission is to change that mindset.

NEGLECTED DISEASES

GLOBAL DISEASES



Emerging Market Value Proposition

Bharat Biotech Strategy

Population

Birth Cohort

Health Care Budgets Increasing

Health Care Budgets Decreasing

Our growth path for future is here

Emerging

5.8 Billion

125 Million

Low Value

High Volume

Products R&D Pipeline Projects Recognition Fast Facts Issues

Developed

0.75 Billion

7.5 Million

High Value

Low Volume



Products




Product Launches

Launching soon Japanese Encephalitis - JENVAC

Dr. A.P.J. Abdul Kalam Former President of India, launching

Dr. John Robbins Father of Polysaccharide Vaccine National Institute of Health, USA, launching

Dr. Julie Gerberding Former Director of the U.S. Centers for Disease Control, launching

Issues Fast Facts



Vaccines

Wide Product Portfolio

S. No. Vaccine Brand

1 DPT+ Hep B + Hib Comvac 5 ®

2 DPT+ Hep B Comvac 4-Hb ®

3 DPT; TT, DT Comvac 3 ™

4 Hep B Revac B+ ®

5 Hep B Revac B mcf ®

6 Hib BioHib ™

7 Typhoid TYPBAR ®

8 OPV Trivalent BIOPOLIO ®

9 OPV Monovalent Type-1 BIOPOLIO M1 ™

10 OPV Monovalent Type-3 BIOPOLIO M3 ™

11 OPV Bivalent BIOPOLIO B1/3 ™

Products R&D Pipeline Projects Recognition Issues Fast Facts


1 Typhoid TYPBAR ®

2 Rabies INDIRAB ®

3 Influenza HN VAC ™


1 Typhoid TYPBAR ®

2 Influenza HN VAC ™

Children & Adult

Traveler

Children



Bio-therapeutics

Wide Product Portfolio


S. No. Bio-therapeutic Brand

1 Low Molecular Weight Heparin Enoxaparin Sodium Injection

BIOENOX ®

2 Probiotic Yeast BIOGIT™

3 Heparin Sodium Injection HEPASOLV™

4 Recombinant Human Epidermal Growth Factor

REGEN-D ®

5 Recombinant Human Epidermal Growth Factor, Silver Sulfadiazine & Chlorexidine Gluconate Cream

SLVRGEN ®

6 Zinc with ORS ZELECT ®



Product Distribution

More than 2 Billion doses delivered




More than 2 Billion doses delivered


Korea

Nepal

Philippines

Brazil

(ANVISA)

Sri Lanka

Saudi Arabia

Colombia

(INVIMA)

Ghana Kenya Congo

Turkey Kazakhstan

Uganda

Syria

Malawi

Ukraine

Belarus

Ivory Coast

Accreditation

WHO



R&D Pipeline




Pipeline Products

1st Time in the world Typhoid Conjugate Vaccine

S. No. Vaccines Product Development

Preclinical Testing Phase I Phase II Phase III Commercial

License

1 Rotavirus 2014

2 Typhoid Conjugate 2012

3 Japanese Encephalitis 2012

4 Chikungunya 2014

5 Malaria PvRII 2015

6 Staph Aureus MRSA 2016

7 Human Papilloma virus 2015

8 Acellular Pertussis 2014

9 Tetanus (meat Free) 2014

Therapeutics Product Development

Preclinical Testing Phase I Phase II Phase III Commercial

License

1 THR-100 2012

2 Lysostaphin (USFDA) 2014

3 r Human Serum Albumin 2014

Issues Fast Facts



Projects



New Vaccine Development S. No. Product Fund

Bill & Melinda Gates Foundation

1 Rota Virus Vaccine ($ 50 Mn)

2 Malaria Vaccine (Vivax) ($ 2 Mn)

EMVI (European Economic Community) & ICGEB

1 Malaria Vaccine - 1 (Falciparum) ($ 2 Mn)

2 Malaria Vaccine - 2

3 Malaria Vaccine - 3

In-House Projects

1 Dengue Vaccine (ICGEB, Delhi)

2 FALVAC Malaria Vaccine (Multi) - CDC-Atlanta

3 Staph Aureus Vaccine

4 Chickungunya Vaccine

5 Typhoid Conjugate Vaccine

6 Human Papilloma virus




Recognition



Recognition of Achievements

Young Enterprising Company


JRD TATA Best Entrepreneur award FICCI Award Excellence in Science

Best Performance in Technology

Marico Foundation Innovation Award

TDB National award DBT-award for Product & Process



“Our mission is to address the health care needs of emerging markets, drive innovation, be a front runner in research and development of

new vaccines and bio-therapeutics”

Mission 7 Billion

Dr. Krishna M. Ella Chairman & Managing Director



Thank You

Address


Genome Valley, Hyderabad.

Andhra Pradesh- - 500 078 INDIA

Tel.: +91 40 2348 0567 Fax: +91 40 2348 0560

[email protected] www.bharatbiotech.com


mailto:[email protected]


Documents

Bharat Biotech Company Prasxfd